# Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults

> **NCT02802631** · PHASE1 · COMPLETED · sponsor: **Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)** · enrollment: 69 (actual)

## Conditions studied

- Normal Healthy Volunteers

## Interventions

- **DRUG:** Minocin (minocycline) for Injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02802631
- **Lead sponsor:** Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2018-02-08
- **Final completion:** 2018-02-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802631, "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02802631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*